Trimetrexate in prostatic cancer: Preliminary observations on the use of prostate-specific antigen and acid phosphatase as a marker in measurable hormone-refractory disease

Journal of Clinical Oncology

Volumn 8, Issue 11, 1990, Pages 1830-1838

  Scher, Howard I ^a   Curley, Tracy ^b   Geller, Nancy ^b   Engstrom, C ^b   Dershaw, D David ^b   Lin, Shiow Yun ^b   Fitzpatrick, Kelly ^b   Nisselbaum, Jerome ^b   Schwartz, Morton ^b   Bezirdjian, Lawrence ^b   Eisenberger, Mario ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; PROSTATE SPECIFIC ANTIGEN; TRIMETREXATE;

ADULT; AGED; CANCER EPIDEMIOLOGY; CLINICAL ARTICLE; CONFERENCE PAPER; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL; PROSTATE CANCER;

ACID PHOSPHATASE; AGED; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; HUMAN; MALE; MIDDLE AGE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; QUINAZOLINES; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; TIME FACTORS; TRIMETREXATE; TUMOR MARKERS, BIOLOGICAL;

EID: 0025186406     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1990.8.11.1830     Document Type: Article

References (38)

1. Scher H, Yagoda A: Clinical trials in prostatic cancer: Methodology and controversies, in Bruce AW, Trachtenberg J (eds): Adenocarcinoma of the Prostate. New York, NY, Springer Verlag, 1987, pp 197-220
2. Scher H, Curley T, Geller NL, et al: Gallium nitrate in prostatic cancer: Evaluation of antitumor activity and effects on bone turnover. Cancer Treat Rep 71:887-893, 1987
3. Hopkins S, Palmieri GM, Niell HB, et al: Total and nondialyzable hydroxyproline excretion in stage 2 prostate cancer. Cancer 53:117-124, 1984
4. Moopan U, Kim H, Wang J, et al: Use of urinary hydroxyproline excertion as tumor marker in diagnosis and follow-up of prostate cancer. Prostate 4:397-401, 1983
5. Brenckman WD Jr, Lastinger LB, Sedor F: Unpredictable fluctuations in serum acid phosphatase activity in prostatic cancer. JAMA 245:2501-2504, 1981
6. Nissenkorn I, Mickey DD, Miller DB, et al: Circadian and day-to-day variation of prostatic acid phosphatase. J Urol 127:1122-1124, 1982
7. Mannini D, Maver P, Aiello E, et al: Spontaneous circadian fluctuations of prostate specific antigen and prostatic acid phosphatase serum activities in patients with prostatic cancer. Urol Res 16:9-12, 1988
8. Zweig M, Idhe D: Assessment of serum and enzymatic prostatic acid phosphatase and radioimmune creatine kinase BB for monitoring response to therapy in metastatic prostatic carcinoma. Cancer Res 45:3945-3952, 1985
9. Manni A, Bartholomew M, Caplan R, et al: Androgen priming and chemotherapy in advanced prostate cancer: Evaluation of determinants of clinical outcome. J Clin Oncol 6:1456-1466, 1988
10. Maatman TJ, Gupta MK, Montie JE: The role of serum prostatic acid phosphatase as a tumor marker in men with advanced adenocarcinoma of the prostate. J Urol 132:58-60, 1984
11. Wang MC, Papsidero LD, Kuriyama M, et al: Prostate antigen: A new potential marker for prostatic cancer. Prostate 2:89-96, 1981
12. Papsidero LD, Wang MC, Valenzuela LA, et al: A prostate antigen in sera of prostatic cancer patients. Cancer Res 40:2428-2432, 1980
13. Stamey TA, Kabalin JN: Prostate specific antigen in diagnosis and treatment of adenocarcinoma of prostate. I. Untreated patients. J Urol 141:1070-1075, 1989
14. Hudson MA, Bahnson RR, Catalona WJ: Clinical use of prostate specific antigen in patients with prostate cancer. J Urol 142:1011-1017, 1989
15. Ercole CJ, Lange PH, Mathisen M, et al: Prostatic specific antigen and prostatic acid phosphatase in monitoring and staging of patients with prostatic cancer. J Urol 138:1181-1184, 1987
16. Ferro MM, Barnes I, Robert JBM, et al: Tumour markers in prostatic carcinoma. A comparison of prostate-specific antigen with acid phosphatase. Br J Urol 60:69-73, 1987
17. Stamey TA, Kabalin JN, Ferrari M, et al: Prostate specific antigen in diagnosis and treatment of adenocarcinoma of prostate. IV. Anti-androgen treated patients. J Urol 141:1088-1090, 1989
18. Matzkin H, Lewyshon O, Ayalon D, et al: Changes in prostate-specific markers under chronic gonadotropin-releasing hormone analogue treatment of stage D prostatic cancer. Cancer 63:1287-1291, 1989
19. Eisenberger MA, Simon R, O'Dwyer PJ, et al: A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic adenocarcinoma. J Clin Oncol 3:827-841, 1985
20. Tannock IF: Is there evidence that chemotherapy is of benefit to patients with carcinoma of the prostate? J Clin Oncol 3:1013-1021, 1985
21. Elslager EF, Davoll J: Synthesis of fused pyrimidines as folate antagonists, in Castle RN, Townsend LB (eds): Lectures in Heterocyclic Chemistry vol 2. Orem UT, Hetero Corp, 1974,pp s97-s133.
22. Lin JT, Bertino JR: Trimetrexate: A second generation folate antagonist in clinical trial. J Clin Oncol 5:2032-2040, 1987
23. Kamen BA, Eibl B, Cashmore AR, et al: Uptake and efficacy of trimetrexate (TMQ), 2,4-diamino-5-methyl-6-[3,4,5-trimethoxyanilino) methyl]quinazoline), a non-classical antifolate in methotrexate-resistant leukemia cells in vitro. Biochem Pharmacol 33:1697-1699, 1984
24. Loening SA, Beckley S, Brady MF, et al: Comparison of estramustine phosphate, methotrexate and cis-platinum in patients with advanced, hormone refractory prostate cancer. J Urol 129:1001-1006, 1983
25. Schwartz MK, Nisselbaum J, Stone N, et al: A comparison of the Hybritech immunoradiometric and immunoenzymetric assays of prostate specific antigen (PSA). Clin Chem 33:928, 1987
26. Scher H, Yagoda A, Watson RC, et al: Phase II evaluation of Adriamycin in bidimensionally measurable prostatic adenocarcinoma. J Urol 131:1099-1102, 1985
27. Bruchovsky N, Rennie PS, Goldenberg SL: Mechanism and effects of androgen withdrawal therapies in Klosterhalfen, H (ed): Endocrine Management of Prostatic Cancer. New York, NY, Walter de Gruyter, 1988, pp 3-15
28. Scher H, Yagoda A: Bone metastases: Pathogenesis, treatment and rationale for use of resorption inhibitors. Am J Med 82:6-28, 1987 (Suppl 2A)
29. Pollen JJ, Witztum K, Asjburn WL: The flare phenomenon on radionuclide bone scan in metastatic prostate cancer. Am J Roentgenol 142:773-776, 1984
30. Pontes JE: Biological markers in prostate cancer. J Urol 130:1037-1047, 1983
31. Heller JE: Prostatic acid phosphatase: Its current clinical status. J Urol 13:1091-1103, 1987
32. Stamey TA, Yang N, Hay AR, et al: Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 317:909-916, 1987
33. Kuriyama M, Wang MC, Lee CL, et al: Multiple marker evaluation in human prostate cancer with the use of tissue-specific antigens. JNCI 68:99-104, 1982
34. Ford TF, Butcher DN, Masters JRW, et al: Immunocytochemical localisation of prostate-specific antigen: Specificity and application to clinical practice. Br J Urol 57:50-55, 1985
35. Jones WG: Do we continue hormonal treatment after hormone resistance? in Murphy GP, Khoury S (eds): Therapeutic Progress in Urological Cancers. New York, NY, Liss 1989, pp 331-336
36. Fowler JE, Whitmore WF: The response of metastatic adenocarcinoma of the prostate to exogenous testosterone. J Urol 126:372-375, 1981
37. Chodak G: Leuteinizing hormone releasing hormone agonist for the treatment of prostate cancer. Urology 33:42-44, 1989 (suppl)
38. Torti F, Aston D, Lum BL, et al: Weekly doxorubicin in endocrine refractory carcinoma of the prostate. J Clin Oncol 1:377-384, 1983